Aclaris Therapeutics Q2 revenue beats analyst estimates
ACRS•Outlook for ATI-052 development
- Aclaris expects top line results from Phase 1b ATI-052 trials in asthma and atopic dermatitis in H2 2026
- Company plans to initiate Phase 2b ATI-052 program in asthma and atopic dermatitis in Q4 2026
- Aclaris expects its cash position to fund operations through the end of 2028
Result drivers and analyst coverage
-
R&D SPENDING - Higher research and development expenses driven by ATI-052 clinical and manufacturing costs
-
ROYALTY REVENUE - Six-month revenue increase attributed to higher royalties from Lilly and Sun Pharma license agreements
-
G&A COSTS - General and administrative expense increase due to higher professional, legal, and personnel expenses
-
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
-
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
-
Wall Street's median 12-month price target for Aclaris Therapeutics, Inc. is $10.00, about 57.2% above its August 5 closing price of $6.36
